Mesoblast Limited: financial analysis
Ratios worked out from 10 fiscal years of Mesoblast Limited's statements, compared with 665 companies in Biotechnology.
Mesoblast Limited scorecard#
Passes 6 of the 14 checks that could be worked out: strongest in financial health (3 of 4), weakest in profitability (0 of 3). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth3 of 6
- ✓Revenue grew in the newest year191.5%Revenue up 191.5% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years19.0%19.0% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median19.0%19.0% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.08 vs -0.09Diluted EPS -0.08 in fiscal 2025 against -0.09 the year before (report's currency).
- ✗Net income higher than five years earlier-$102 M-$102 M in fiscal 2025 against -$78 M in 2020.
- ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
Profitability0 of 3
- ✗Profitable in the newest year-$102 MNet income -$102 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-18.9%-18.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 4
- ✓Short-term assets cover short-term liabilities2.0×Current ratio 1.99 at the end of fiscal 2025.
- ✓Debt below equity0.1×Debt to equity 0.11 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $94 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year22.4%Diluted shares up 22.4% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- More cash than debt: net cash of $94 million.
Worth a look
- Net loss of $102 million, the 10th loss-making year in a row.
- Free cash flow was negative: -$51 million.
- The share count rose 22.4% in the year.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseyes
- Cash from operations exceeds profityes
- Long-term debt fell against assetsyes
- Current ratio roseyes
- No new shares issuedno
- Gross margin roseno
- Asset turnover roseyes
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 70.2% | — | — | — | — | 74.8% | 43% | |
| Net margin | -593.8% | — | — | -894.7% | — | -68.9% | 8% | |
| Return on equity | -19.0% | -17.9% | -16.4% | -16.9% | -17.5% | -61.0% | 81% | |
| Return on assets | -14.1% | -13.1% | -12.3% | -13.0% | -13.4% | -44.4% | 80% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 191.5% | -21.3% | -26.5% | 37.4% | -76.9% | 15.8% | 92% | |
| Revenue growth, 3 years a year | 19.0% | -7.4% | -38.5% | -15.2% | -24.6% | 12.9% | 58% | |
| Revenue growth, 5 years a year | -11.8% | -18.8% | -15.4% | 33.5% | -29.5% | 15.4% | 10% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | 0.11× | 0.21× | 0.20× | 0.18× | 0.07× | 0.26× | 67% | |
| Net debt | $-94 M | $38 M | $31 M | $31 M | $-96 M | $-16 M | 74% | |
| Current ratio | 1.99× | 1.18× | 1.95× | 1.36× | 1.57× | 4.39× | 22% | |
| Equity share of assets | 76.1% | 71.8% | 75.0% | 75.1% | 78.1% | 64.7% | 63% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-51 M | $-49 M | $-64 M | — | — | $-40 M | 45% | |
| Free cash flow margin | -294.4% | -825.9% | -847.1% | — | — | -61.5% | 25% | |
| Capital spending share of revenue | 4.0% | 4.6% | 3.5% | — | — | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.02× | 0.01× | 0.01× | 0.01× | 0.01× | 0.26× | 5% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).
Source: Mesoblast Limited's statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that Mesoblast Limited is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Mesoblast Limited